Week In Review: MediLink And BioNTech Form $1.8B ADC Partnership

seekingalpha06-02

Suzhou MediLink partners with BioNTech to use its antibody-drug conjugate platform, receiving an upfront payment of $25 million and up to $1.8 billion in milestones.Asahi Kasei offers $1.1 billion to ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2440112441?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2054772178/image_2054772178.jpg","is_english":true,"pubTime":"2024-06-02 15:00","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2440112441","market":"sh","top_or_hot":-1,"title":"Week In Review: MediLink And BioNTech Form $1.8B ADC Partnership","media":"seekingalpha","content":"<div>\n<p>Suzhou MediLink partners with BioNTech to use its antibody-drug conjugate platform, receiving an upfront payment of $25 million and up to $1.8 billion in milestones.Asahi Kasei offers $1.1 billion to ...</p>\n\n<a href=\"https://seekingalpha.com/article/4696959-week-in-review-medilink-and-biontech-form-1-8b-adc-partnership\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Week In Review: MediLink And BioNTech Form $1.8B ADC Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWeek In Review: MediLink And BioNTech Form $1.8B ADC Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-02 15:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4696959-week-in-review-medilink-and-biontech-form-1-8b-adc-partnership><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Suzhou MediLink partners with BioNTech to use its antibody-drug conjugate platform, receiving an upfront payment of $25 million and up to $1.8 billion in milestones.Asahi Kasei offers $1.1 billion to ...</p>\n\n<a href=\"https://seekingalpha.com/article/4696959-week-in-review-medilink-and-biontech-form-1-8b-adc-partnership\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2361044949.HKD","symbol_name":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","start_time":0,"source_url":"https://seekingalpha.com/article/4696959-week-in-review-medilink-and-biontech-form-1-8b-adc-partnership","article_id":"2440112441","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2054772178/image_2054772178.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2440112441","pubTimestamp":1717311600,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Suzhou MediLink partners with BioNTech to use its antibody-drug conjugate platform, receiving an upfront payment of $25 million and up to $1.8 billion in milestones.Asahi Kasei offers $1.1 billion to ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","BK4231":"零售房地产信托","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","MRK":"默沙东","BNR":"燃石医学","ADC":"艾格里房产","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU0122379950.USD":"贝莱德世界健康科学A2","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","BK4548":"巴美列捷福持仓","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","SG9999001176.USD":"United Global Healthcare Acc USD","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","CALT":"Calliditas Therapeutics AB","GYRE":"Gyre Therapeutics","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SMMT":"Summit Therapeutics PLC","AHKSY":"Asahi Kaisei Corp.","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4534":"瑞士信贷持仓","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","AKESF":"AKESO INC.","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","ESALF":"Eisai Co., Ltd.","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4080":"零售业房地产投资信托","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BAYZF":"Bayer A.G.","BK4535":"淡马锡持仓","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BNTX":"BioNTech SE","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","CSPHF":"CSTONE PHARMACEUTICALS"},"translate_title":"一周回顾：MediLink和BioNTech建立$1.8 B ADC合作伙伴关系","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AHKSY":1,"SMMT":1,"MRK":1,"GYRE":1,"ESALF":1,"CSPHF":1,"CALT":1,"BNTX":1,"BNR":1,"ADC":1,"BAYZF":1,"AKESF":1},"content_text":"Suzhou MediLink partners with BioNTech to use its antibody-drug conjugate platform, receiving an upfront payment of $25 million and up to $1.8 billion in milestones.Asahi Kasei offers $1.1 billion to acquire Calliditas Therapeutics, aiming to expand its presence in healthcare and enter the areas of immunology and transplantation.Bio-Thera Solutions sells European rights for its biosimilar to STADA Arzneimittel in a $157.5 million agreement, targeting the treatment of arthritis and autoimmune disorders.anusorn nakdee/iStock via Getty Images Deals and Financings Suzhou MediLink partnered with Germany's BioNTech (BNTX) to use MediLink's TMALIN® antibody-drug conjugate ('ADC') platform to discover ADC candidates for several novel targets chosen by BioNTech (see story). MediLink will receive an upfront payment of $25 million and up to $1.8 billion in milestones, plus tiered royalties. MediLink has first negotiation rights to commercialize any candidates in Mainland China. The two companies are very familiar with each other. In October 2023, MediLink announced a deal worth up to $1.1 billion granting BioNTech global rights (ex-China) for MediLink's next-gen anti-HER3 ADC. Asahi Kasei (OTCPK:AHKSY), a Japanese conglomerate known mainly for its chemicals and building materials, made a $1.1 billion offer to buy Calliditas Therapeutics (CALT) of Sweden (see story). Calliditas is a company focused on rare diseases with one FDA approved drug, Tarpeyo (a delayed-release formulation of the steroid budesonide) for primary immunoglobulin A nephropathy ('IgAN'). IgAN is a chronic kidney disease caused by the buildup of antibodies. Asahi Kasei has a medical subsidiary that provides filters for dialysis machines and other conditions. The company wants to have a larger presence in healthcare and plans to expand into the areas of immunology and transplantation. Bio-Thera Solutions, a Guangzhou biopharma focused on innovative and biosimilar drugs, sold European rights for a biosimilar to Germany's STADA Arzneimittel (STDAF) in a $157.5 million agreement (see story). The biosimilar is Golimumab (BAT2506), a human IgG1 monoclonal antibody that targets tumor necrosis factor alpha (TNF- α), a pro-inflammatory molecule. BAT2506 is a proposed biosimilar to Janssen's Simponi® (golimumab), which is approved to treat arthritis and other autoimmune disorders. In 2023, Bio-Thera completed a China Phase III trial of BAT2506 in psoriatic arthritis patients, but it hasn't released the results. Suzhou CStone Pharma (OTCPK:CSPHF) is selling marketing rights for its lead drug, an anti-PD-L1 monoclonal antibody known as sugemalimab, to Switzerland's Ewopharma in a deal worth $51 million upfront plus milestones. Ewopharma will own commercial rights for sugemalimab in Switzerland and 18 Central Eastern European countries. CStone will book revenues from supplying the drug to Ewopharma. Ewopharma will be responsible for pricing, reimbursement, sales & marketing and distribution. The EMA and UK MHRA are reviewing the MAA for sugemalimab in combination with chemotherapy as the first-line treatment of metastatic NSCLC. Guangzhou Burning Rock Biotech (BNR) will collaborate with Germany's Bayer (OTCPK:BAYZF) to develop companion diagnostic assays ('CDX') based on next-generation sequencing with the goal of improving treatment choices for China patients with cancer. The collaboration will jointly develop NGS-based companion diagnostic products in China for Bayer's growing portfolio of precision cancer therapies. Shanghai HuidaGene Therapeutics, a company that develops CRISPR-based genomic medicines, partnered its high-fidelity Cas12 CRISPR nuclease (hfCas12Max) with Synthego of Redwood City, CA. HuidaGene granted Synthego non-exclusive manufacturing and commercialization rights for the hfCas12Max nuclease and optimized gRNA for research. Synthego will also have the right to sublicense the nuclease for therapeutic use. Synthego offers novel CRISPR solutions for developing cell and gene therapies. The companies said the partnership reflects the clinical utility of hfCas12Max and complements Synthego's focus on advanced GMP manufacturing. Terms of the agreement were not disclosed. Trials and Approvals Guangzhou's Akeso (OTCPK:AKESF) reported that its bispecific antibody, ivonescimab, a combination of PD-1 and VEGF, posted better progression-free survival results than Merck's (MRK) Keytruda in patients with non-small cell lung cancer. It is the first time Keytruda was bested by another PD-1 candidate, according to the company. The data came from an interim analysis of ivonescimab in a China Phase III trial in NSCLC patients with positive PD-L1 expression. Specific data will be presented in an upcoming scientific meeting. In late 2022, Summit Therapeutics (SMMT) in-licensed US/EU/Japan rights for ivonescimab in a $5 billion deal. San Diego's Gyre Therapeutics (GYRE) was approved to begin China trials of F230, a selective endothelin receptor antagonist, to treat pulmonary arterial hypertension. Gyre is a clinical-stage biotech that develops anti-fibrotic therapeutics for several chronic organ diseases. The China trial will be run by Gyre Pharmaceuticals, an indirectly controlled Gyre subsidiary located in Beijing. F230 was originally licensed from Eisai (OTCPK:ESALF) via Gyre's indirect majority stockholder, GNI Group Ltd of Japan. Disclosure: None.  Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha editors.  Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2440112441"}